Avacta Group PLC AVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 50.20
- Day Range
- GBX 48.00–52.33
- 52-Week Range
- GBX 39.50–166.98
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 17.63 Bil
- Volume/Avg
- 1.8 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 148
- Website
- https://www.avacta.com
Comparables
Valuation
|
Metric
|
AVCT
|
BVXP
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 25.46 | 20.47 |
Price/Book Value | 3.68 | 18.26 | 5.82 |
Price/Sales | 6.60 | 15.61 | 4.70 |
Price/Cash Flow | — | 23.24 | 21.77 |
Price/Earnings
AVCT
BVXP
AZN
Financial Strength
|
Metric
|
AVCT
|
BVXP
|
AZN
|
|---|---|---|---|
Quick Ratio | 1.21 | 6.69 | 0.69 |
Current Ratio | 1.29 | 7.04 | 0.89 |
Interest Coverage | −1.02 | — | 5.45 |
Quick Ratio
AVCT
BVXP
AZN
Profitability
|
Metric
|
AVCT
|
BVXP
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | −46.19% | 68.76% | 57.63% |
Return on Equity (Normalized) | −124.79% | 77.21% | 151.23% |
Return on Invested Capital (Normalized) | −48.68% | 76.10% | 84.88% |
Return on Assets
AVCT
BVXP
AZN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bkglbbtxz | Vntj | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cskhphy | Pccfjh | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fdxtxgxhd | Hgnvkg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cczztnzz | Hnxjy | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Mnbrswwq | Jwsh | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Rnlkkxhrc | Hbtgq | $29.2 Bil | |||
| Moderna Inc
MRNA
| Ycyjrdygc | Lkmx | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rgtmkzxw | Lyh | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gmmcfcycg | Ztmcbv | $13.2 Bil | |||
| Incyte Corp
INCY
| Hptwdxk | Hvftxhp | $13.0 Bil |
United States